HUTCHMED (China) Analyst Ratings
HUTCHMED (China) Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | -9.72% | Goldman Sachs | $15 → $17 | Maintains | Neutral |
| 09/05/2023 | 165.53% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 07/24/2023 | 165.53% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 08/09/2022 | -15.03% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
| 08/02/2022 | -25.65% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
| 09/22/2021 | 144.29% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
| 08/03/2021 | 176.16% | Jefferies | → $52 | Initiates Coverage On | → Buy |
| 03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 02/20/2020 | 101.81% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
| 10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
| 03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/10/2023 | -9.72% | 高盛 | 15 美元 → 17 美元 | 維護 | 中立 |
| 09/05/2023 | 165.53% | 坎託·菲茨傑拉德 | → 50 美元 | 重申 | 超重 → 超重 |
| 2023 年 7 月 24 日 | 165.53% | 坎託·菲茨傑拉德 | → 50 美元 | 重申 | 超重 → 超重 |
| 08/09/2022 | -15.03% | 高盛 | 14 美元 → 16 美元 | 維護 | 中立 |
| 08/02/2022 | -25.65% | 高盛 | 16 美元 → 14 美元 | 維護 | 中立 |
| 2021 年 9 月 22 日 | 144.29% | 高盛 | → 46 美元 | 降級 | 買入 → 中性 |
| 08/03/2021 | 176.16% | 傑富瑞集團 | → 52 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/13/2020 | — | 坎託·菲茨傑拉德 | 啓動覆蓋範圍開啓 | → 超重 | |
| 02/20/2020 | 101.81% | 高盛 | → 38 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/19/2019 | — | CLSA | 啓動覆蓋範圍開啓 | → 購買 | |
| 2019 年 10 月 23 日 | — | B of A 類證券 | 恢復 | → 購買 | |
| 03/04/2019 | — | 德意志銀行 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for HUTCHMED (China) (HCM)?
和黃醫藥（中國）（HCM）的目標價格是多少？
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Goldman Sachs on November 10, 2023. The analyst firm set a price target for $17.00 expecting HCM to fall to within 12 months (a possible -9.72% downside). 3 analyst firms have reported ratings in the last year.
高盛於2023年11月10日公佈了和黃醫藥（中國）（納斯達克股票代碼：HCM）的最新目標股價。該分析公司將目標股價定爲17.00美元，預計HCM將在12個月內跌至-9.72％（可能下跌9.72％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for HUTCHMED (China) (HCM)?
和黃醫藥（中國）（HCM）的最新分析師評級是多少？
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Goldman Sachs, and HUTCHMED (China) maintained their neutral rating.
和黃醫藥（中國）（納斯達克股票代碼：HCM）的最新分析師評級由高盛提供，和黃醫藥（中國）維持中性評級。
When is the next analyst rating going to be posted or updated for HUTCHMED (China) (HCM)?
和黃醫藥（中國）（HCM）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與和黃醫藥（中國）的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。和黃醫藥（中國）的最新評級是在2023年11月10日公佈的，因此您應該預計下一個評級將在2024年11月10日左右公佈。
Is the Analyst Rating HUTCHMED (China) (HCM) correct?
和黃醫藥（中國）（HCM）的分析師評級是否正確？
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a maintained with a price target of $15.00 to $17.00. The current price HUTCHMED (China) (HCM) is trading at is $18.83, which is out of the analyst's predicted range.
雖然評級是主觀的，而且會發生變化，但和黃醫藥（中國）（HCM）的最新評級維持不變，目標股價爲15.00美元至17.00美元。和黃醫藥（中國）（HCM）目前的交易價格爲18.83美元，超出了分析師的預期區間。